biostudies-literatureChang ELProject Data Spheree011049https://www.ebi.ac.uk/biostudies/studies/S-EPMC11979595biostudies-literatureUnknown13(4)Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs.Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings Journal for immunotherapy of cancerConsensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.PMC11979595N/AShariff AReynolds KLMantopoulos DChang ELChen JJLiu RYoon MKBerkenstock MDeLott LBSen HNRine JHuynh KPless MBhatti MTEgan RASobrin LMcDunn JCostello FPapaliodis GFreitag SKFraser CLSubramanian PSGangaputra SJohnson DBKombo NGordon LKRubin KMLee AGKeyhanian KChodosh JKramer MPimkina JLobo-Chan AMTsui EChwalisz BKDinkin MLevy MDalvin LAGuidon ACfalseConsensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors.Ophthalmic immune-related adverse events (Eye-irAEs) from immune checkpoint inhibitors can cause visual morbidity. The absence of standardized definitions for Eye-irAEs not only impedes the development of evidence-based treatments but also progress in translational research. The objective of this study was to develop consensus guidance for an approach to Eye-irAEs.Four ophthalmic physicians (uveitis specialists and neuro-ophthalmologists) drafted Eye-irAE consensus guidance and definitions, which were reviewed by the multidisciplinary Eye-irAE definition panel. The panel was divided into Group A (Neuro-ophthalmology/Orbital Disease) and Group B (Uveitis/Ocular Surface Disease). A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings 2025-01-01T00:00:00Z2025 Apr2025-07-07T03:10:06.964Z2025-07-07T03:10:06.964ZS-EPMC119795954019960710.1136/jitc-2024-011049